Litigation

Recent Posts

U.S. Supreme Court Will Rule On Preemption Of Generic Drug Design Defect Claim
Posted on 3 Dec 2012 by Tom Moylan

WASHINGTON, D.C. - (Mealey's) The U.S. Supreme Court on Nov. 30 said it will review a First Circuit U.S. Court of Appeals ruling that a defective design claim involving a generic drug is not preempted by federal law, placing in jeopardy a $21 million... Read More

Tags: Karen Bartlett , nonsteroidal anti-inflammatory drug , Clinoril , preemption , toxic epidermal necrolysis , Stevens-Johnson syndrome , drug litigation , First Circuit , Mutual Pharmaceutical Company v. Karen L. Bartlett , Litigation , generic drug , defective design claim , U.S. Supreme Court , sulindac , verdict , Mutual Pharmaceutical Co.

Levaquin Compensatory Verdict Affirmed By 8th Circuit; Punitive Verdict Reversed
Posted on 3 Dec 2012 by Tom Moylan

ST. LOUIS — (Mealey’s) The Eighth Circuit U.S. Court of Appeals on Nov. 30 unanimously affirmed denial of judgment as a matter of law or new trial for compensatory damages in the first Levaquin multidistrict litigation bellwether trial but... Read More

Tags: levofloxacin , Eighth Circuit , John Schedin v. Ortho-McNeil-Janssen Pharmaceuticals , Levaquin , compensatory damages , drug litigation , OMJP , Litigation , multidistrict litigation , antibiotic , corticosteroids , Ortho-McNeil-Janssen Pharmaceuticals , punitive damage , John Schedin , verdict , In Re: Levaquin Products Liability Litigation